KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Johnson & Johnson (JNJ) Research & Development (2016 - 2026)

Johnson & Johnson's Research & Development history spans 18 years, with the latest figure at $3.5 billion for Q1 2026.

  • On a quarterly basis, Research & Development rose 9.36% to $3.5 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $411.0 million, a 97.57% decrease, with the full-year FY2025 number at $109.0 million, down 99.37% from a year prior.
  • Research & Development hit $3.5 billion in Q1 2026 for Johnson & Johnson, up from -$10.3 billion in the prior quarter.
  • Over the last five years, Research & Development for JNJ hit a ceiling of $6.2 billion in Q1 2022 and a floor of -$10.3 billion in Q4 2025.
  • Historically, Research & Development has averaged $2.3 billion across 5 years, with a median of $3.5 billion in 2025.
  • Biggest five-year swings in Research & Development: plummeted 344.43% in 2023 and later soared 152.34% in 2024.
  • Tracing JNJ's Research & Development over 5 years: stood at $3.5 billion in 2022, then plummeted by 390.44% to -$10.1 billion in 2023, then soared by 152.34% to $5.3 billion in 2024, then tumbled by 294.49% to -$10.3 billion in 2025, then soared by 134.23% to $3.5 billion in 2026.
  • Business Quant data shows Research & Development for JNJ at $3.5 billion in Q1 2026, -$10.3 billion in Q4 2025, and $3.7 billion in Q3 2025.